2017 Fiscal Year Final Research Report
To develop a new therapeutic method targeting AKR1C1 for urothelial carcinoma micrometastasis
| Project/Area Number |
16K20122
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Hokkaido University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2016-04-01 – 2018-03-31
|
| Keywords | 尿路上皮癌 / 転移 / 薬剤耐性 / AKR1C1 |
|---|
| Outline of Final Research Achievements |
The effect of increasing bladder cancer cell cisplatin sensitivity and suppressing cell invasion capacity was observed in fenamic acid type nonsteroidal anti - inflammatory drugs such as flufenamic acid and mefenamic acid which have AKR1C1 inhibitory effect. In the study using clinical specimens, AKR1C1 was significantly increased in urothelial carcinoma metastatic site compared with primary site, and the effect of suppressing metastasis by the AKR1C1 inhibitor and enhancing the anticancer drug therapeutic effect on the metastatic lesion was expected. Currently, it is under observation that cisplatin and fenamic acid are administered to mice, and the application amount of fenamic acid is being studied.
|
| Free Research Field |
泌尿器科
|
